Marangoni and colleagues showed that antibody-mediated CD44-targeting in human BC xenografts (HBCx) significantly reduces tumor growth, an effect attributed to the induction of growth-inhibiting factors [105]. This evidence concerns the gene CD44 and neoplasm.